1-800-710-4674

Find a Doctor

Return to Physician Search

Physician Profile

 

Evan Z. Lang, M.D., MS

“I work hard to provide the best care while preserving each patient’s quality of life. My goal is to provide up-to-date knowledge and demonstrate a commitment to excellence.”
Learn More.

Practices

Hematology
Medical Oncology

Locations

Fairfield
Hamilton
Wilmington

Request
appointment

or call
1-800-710-4674

SPECIALTIES

General oncology
Hematology

MEDICAL INTERESTS

Cancer research

PERSONAL INTERESTS

Biking, kayaking, and reading.

LANGUAGE

English and Chinese

MEDICAL SCHOOL

Second Military Medical University, Shanghai, China
Northeastern Ohio Universities College of Medicine

INTERNSHIP

Fairview Hospital, Cleveland Clinic Health System

RESIDENCY

Fairview Hospital, Cleveland Clinic Health System
University Hospitals of Cleveland

FELLOWSHIP

University Hospitals of Cleveland, Ireland Cancer Center

CERTIFICATIONS & LICENSURES

American Board of Internal Medicine, Internal Medicine
American Board of Internal Medicine, Medical Oncology

MEMBERSHIPS

American Medical Association
American Society of Clinical Oncology
Ohio State Medical Association

COMMITTEES

Chair, Cancer Committee, Fort Hamilton Hospital

David M. Waterhouse, Kent C. Shih, Ahmed Zakari, Evan Z. Lang, Michael McCleod, Kathryn Alguire, Nancy W. Peacock, Douglas Flora, Peter G. Ruehlman, Chris Earwood, Johanna C. Bendell. Bevacizumab, Pertuzumab, and Sandostatin for Patients (pts) with Advanced Neuroendocrine Cancers (NET): A Phase ll Study of the Sarah Cannon Oncology Research Consortium. 2012

Eshleman JR, Markowitz SD, Scott P, Lang EZ, Lutterbaugh JD, Goumin Leo, Lee M, Veigl ML, and Sedwick WD. Diverse Hypermutability of Multiple Expressed Sequences of Motifs Present in Cancers with Microsatellite Instability. Oncogene, April 1996

Eshleman, JR, Lang EZ, Bowerfind GK, Parsons R, Vogelstein B, Willson JVK, Veigl M, Sedwick WD, and Markowitz S. Increased Mutation Rate at the hprt Locus Accompanies Microsatellite Instability in Colon Cancer. Oncogene, 10, 33-37, 1995

Eshleman JR, Lang EZ, Lutterbaugh JD, Bowerfind GK, Parson R, Vogelstein B, Willson JKV, Veigl ML, Markowitz SD and Sedwick WD. Molecular Ananlysis of Spontaneous Mutations in Colon Cancer Exhibiting Microsatellite Instability. Proceedings of the American Association for Cancer Research, 36, 145, March 1995

A Phase ll Trial for Panobinostat in Refractory Myelodysplastic Syndromes (MDS) Patients, ASCO Presentation

As a member of our OHC physician team, Dr. Lang has full access to the OHC Clinical Trial research program.

We encourage our patients to discuss all of their healthcare options — including Clinical Trial research programs — with their doctor.

The following are recent reviews provided by actual OHC patients:

"I see five different specialists on a regular basis. I actually look forward to my visits with Dr. Lang. He is always so very kind. He seems genuinely concerned about my well-being. He never rushes through my appointment. He always goes over my blood test results with me. His entire staff is also top notch. They seem to care about me as a person, rather than just another patient. I can't say enough good things about Dr. Lang and his staff. They are simply wonderful! I only wish Dr. Lang were my family doctor and my endocrinologist."

"Dr. Lang is an excellent doctor!"

"Through my treatment, I was cared for with utmost respect."